根据风险评分调整双联抗血小板治疗的持续时间。 - Suppr

Suppr

超能文献

Tailoring duration of DAPT with risk scores.

作者信息

Capodanno Davide, Angiolillo Dominick J

机构信息

Ferrarotto Hospital, University of Catania, Catania, Italy.

University of Florida College of Medicine-Jacksonville, Jacksonville, FL 32209, USA.

出版信息

Lancet. 2017 Mar 11;389(10073):987-989. doi: 10.1016/S0140-6736(17)30591-3.

DOI:10.1016/S0140-6736(17)30591-3

PMID:28291000

Abstract

摘要

相似文献

Tailoring duration of DAPT with risk scores.根据风险评分调整双联抗血小板治疗的持续时间。

Lancet. 2017 Mar 11;389(10073):987-989. doi: 10.1016/S0140-6736(17)30591-3.

Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis.慢性肾脏病合并药物洗脱支架患者双联抗血小板治疗时间的 Meta 分析。

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):810-822. doi: 10.2215/CJN.12901018. Epub 2019 Apr 22.

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.经皮冠状动脉介入治疗和药物洗脱支架置入术后双联抗血小板治疗：系统评价和网络荟萃分析。

Circulation. 2020 Oct 13;142(15):1425-1436. doi: 10.1161/CIRCULATIONAHA.120.046308. Epub 2020 Aug 3.

Long-Term Outcomes and Duration of Dual Antiplatelet Therapy After Coronary Intervention With Second-Generation Drug-Eluting Stents: The Veterans Affairs Extended DAPT Study.第二代药物洗脱支架冠状动脉介入治疗后双联抗血小板治疗的长期结局和持续时间：退伍军人事务部延长 DAPT 研究。

J Am Heart Assoc. 2023 Jan 17;12(2):e027055. doi: 10.1161/JAHA.122.027055. Epub 2023 Jan 16.

Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents.新一代药物洗脱支架治疗患者中双重抗血小板治疗持续时间与血管造影多支血管病变对预后的关联

Circ Cardiovasc Interv. 2016 Nov;9(11). doi: 10.1161/CIRCINTERVENTIONS.116.004256.

Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.PARTHENOPE 试验的原理和设计：在所有接受 PCI 的患者中，比较无聚合物 vs 可生物降解聚合物药物洗脱支架以及个体化 vs 标准双联抗血小板治疗持续时间的两因素、两水平析因比较。

Am Heart J. 2023 Nov;265:153-160. doi: 10.1016/j.ahj.2023.08.001. Epub 2023 Aug 10.

The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation.药物洗脱支架植入术后长期双联抗血小板治疗中平均血小板聚集度的重要性

Cardiovasc Ther. 2016 Jun;34(3):127-37. doi: 10.1111/1755-5922.12177.

Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents.第二代药物洗脱支架治疗患者双联抗血小板治疗持续时间的Meta分析

Am J Cardiol. 2016 Jun 1;117(11):1714-23. doi: 10.1016/j.amjcard.2016.03.005. Epub 2016 Mar 19.

Efficacy of Short-term Dual Antiplatelet Therapy after Implantation of Second-generation Drug-eluting Stents: A Meta-analysis and Systematic Review.第二代药物洗脱支架植入术后短期双联抗血小板治疗的疗效：一项荟萃分析与系统评价

Chin Med Sci J. 2017 Apr 10;32(1):1-12.

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.高出血风险患者经皮冠状动脉介入治疗后使用依维莫司洗脱支架行 1 个月双联抗血小板治疗。

Circ Cardiovasc Interv. 2020 Nov;13(11):e009565. doi: 10.1161/CIRCINTERVENTIONS.120.009565. Epub 2020 Nov 10.

引用本文的文献

Validation of Academic Research Consortium for High Bleeding Risk Definition in East-Asian Patients.东亚患者高出血风险定义学术研究联盟的验证

JACC Asia. 2023 Feb 7;3(3):390-399. doi: 10.1016/j.jacasi.2022.11.012. eCollection 2023 Jun.

Post-PCI Antithrombotic Treatment With High Bleeding Risk.高出血风险患者经皮冠状动脉介入治疗后的抗栓治疗

J Am Coll Cardiol. 2022 Sep 27;80(13):1238-1240. doi: 10.1016/j.jacc.2022.07.015.

Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention.双联抗血小板治疗患者出血并发症的风险评分：如何优化经皮冠状动脉介入治疗后出血风险患者的识别

J Clin Med. 2022 Jun 21;11(13):3574. doi: 10.3390/jcm11133574.

Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches.2022年动脉粥样硬化血栓形成性疾病的抗血小板治疗——从群体到以患者为中心的方法

Front Cardiovasc Med. 2022 Jan 28;9:805525. doi: 10.3389/fcvm.2022.805525. eCollection 2022.

Bleeding avoidance strategies in percutaneous coronary intervention.经皮冠状动脉介入治疗中的出血预防策略。

Nat Rev Cardiol. 2022 Feb;19(2):117-132. doi: 10.1038/s41569-021-00598-1. Epub 2021 Aug 23.

Patient-tailored antithrombotic therapy following percutaneous coronary intervention.经皮冠状动脉介入治疗后的个体化抗栓治疗。

Eur Heart J. 2021 Mar 7;42(10):1038-1046. doi: 10.1093/eurheartj/ehaa1097.

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.急性冠脉综合征伴高出血和缺血风险患者完成 9-12 个月双联抗血小板治疗后，单用氯吡格雷与氯吡格雷加阿司匹林进行延长抗血小板治疗的效果比较：OPT-BIRISK 双盲、安慰剂对照随机试验的原理和设计。

Am Heart J. 2020 Oct;228:1-7. doi: 10.1016/j.ahj.2020.07.005. Epub 2020 Jul 9.

Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR Asia.非 ST 段抬高型心肌梗死患者的延长双联抗血小板治疗：EPICOR Asia 的 2 年研究结果。

Clin Cardiol. 2020 Apr;43(4):346-354. doi: 10.1002/clc.23322. Epub 2020 Jan 22.

Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting.接受冠状动脉支架置入术的抗凝患者抗血栓治疗的不断演变的模式。

Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719891688. doi: 10.1177/1753944719891688.

How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study.心内科医生如何为心肌梗死后超过 1 年的患者选择继续双联抗血小板治疗？EYESHOT 心梗后研究的见解。

Clin Cardiol. 2019 Nov;42(11):1113-1120. doi: 10.1002/clc.23262. Epub 2019 Aug 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验